Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Sangamo Therapeutics excels in 2022 trials, prioritizes innovative programs

Sangamo Therapeutics had a strong year in 2022, focusing on key programs like CAR-Treg and Fabry disease while making strategic decisions to optimize resources.
Positive trial results and FDA alignment signal progress and potential for future collaborations and advancements in treatments.
Challenges include resource reallocation, endpoint validation, and data transparency, which require careful management and strategic planning.
Overall, Sangamo's performance, strengths, and opportunities position the company well for continued growth and innovation in the biopharmaceutical sector.

Sangamo Therapeutics reports strong Q1 revenue and strategic reorganization

Sangamo Therapeutics is strategically reorganizing to focus on neurology, Fabry, and TX200 CAR-Treg programs, aiming to reduce cash burn and enhance operational efficiency.
The company's emphasis on genomic medicines for chronic pain and neurological disorders highlights its commitment to addressing significant unmet medical needs.
While facing capital constraints, Sangamo is exploring financing options and partnerships to support future growth and innovation, balancing patient benefit and safety in clinical advancements.

Sangamo Therapeutics excels in clinical progress and strategic collaborations

Sangamo Therapeutics demonstrates strong performance in clinical and preclinical programs, backed by a solid financial position and strategic collaborations. Challenges include the need for additional funding and ensuring successful trial execution. Opportunities for growth through expanding partnerships and innovative genomic engineering approaches.

Sangamo shifts focus to neurology, eyes partnerships for growth

Sangamo's strategic shift to neurology shows promise but requires navigating challenges of restructuring and resource reallocation.
The company's financial discipline and focus on operational efficiency aim to ensure self-sustainability until Q3 2024 without additional capital raises.
Progress in innovative therapies like CAR-Tregs and AAV capsid evolution positions Sangamo well for advancements in genomic medicine for neurological disorders.
Exploration of partnerships and monetization opportunities present avenues for growth and strategic advancement in Sangamo's therapeutic programs.

Sangamo Therapeutics excels in neurology advancements and financial stability

Sangamo Therapeutics made significant strides in neurology programs, financial stability, and technology advancements, positioning the company for future growth
Challenges in clinical trial navigation and funding require strategic planning, while opportunities in collaborations and partnerships offer avenues for expansion
Overall, Sangamo's focus on innovation, cost efficiency, and strategic collaborations bode well for its continued success in the neurology and gene therapy space

Sangamo Therapeutics reports positive trial results and lucrative collaborations

Sangamo Therapeutics showcased strong performance in their pipeline with positive trial results and progress in the Fabry disease program.
The company's collaboration agreements and innovative technologies position them well for future growth and revenue generation.
While facing challenges in manufacturing and commercialization, Sangamo has significant opportunities in advancing genomic medicines and expanding therapeutic applications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease (SCD). These data are being presented today at the 63rd American Society for Hematology Annual Meeting and Exposition taking place from December 11-14

Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease

Sangamo Therapeutics is ready to present data from their sickle cell and hemophilia A gene therapy programs at ASH. I believe the data could trigger a reversal by year-end. I discuss why I believe the ASH data is so important for both the near-term and long-term outlook for the stock.

Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December

The mean of analysts' price targets for Sangamo (SGMO) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Sangamo (SGMO) Could Surge 64%: Read This Before Placing a Bet

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease.  As of the September 17, 2021 cutoff date, results from the four patients treated in the first two dose cohorts (0.5e13 vg/kg and 1e13 vg/kg) showed that the gene therapy was generally well tolerated.

Why Did Sangamo Stock Jump 20% Today?

Sangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q3 2021 Results - Earnings Call Transcript

Sangamo (SGMO) delivered earnings and revenue surprises of 2.94% and 5.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights. “We are delighted to share clinical data and business updates across several programs demonstrating that Sangamo has three important assets progressing toward late-stage development. Our gene therapy portfolio is advancing with accumulating safety and efficacy data in our Fabry and hemophilia A pro

Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. As of the September 17, 2021 cutoff date, results from the four patients treated in the first two dose cohorts (0.5e13 vg/kg and 1e13 vg/kg) showed that isaralgagene civaparvovec was gen

Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021. The press release will be followed by a conference call at 9:15 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business and clinical updates. The confe

Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to Decline

Sangamo has transitioned to what they called Wave 2 a couple years ago. Biogen and Novartis have partnered with Sangamo to pursue gene regulation. These partnerships are actively being grown with two executives leaving Novartis to join Sangamo.

Sangamo: An Emerging Neurogenetic Therapies Leader

Sangamo Therapeutics continues to develop their impressive pipeline of both wholly-owned and partnered programs. Sangamo has the potential to receive up to $7B in milestone payments from these pipeline programs.The company's gene therapy for hemophilia A is moving closer to a BLA. The company expects to report updated safety and efficacy results that should reveal SB-525's durability.

Sangamo Therapeutics: Finding An Opportunity To Reload

Editas Medicine

Intellia Therapeutics

Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a single stock, Intellia Therapeutics, which is up by about 3x year-to-date, after the company.

Will Moderna's Interest Boost Gene Editing Stocks?

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 2:55pm Eastern Time. The virtual session will be webcast live and may be accessed on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will be available on the Sangamo Therapeutic

Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2021 Results - Earnings Call Transcript

Sangamo (SGMO) delivered earnings and revenue surprises of -10.00% and -6.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results. “This is an exciting time at Sangamo, as we look forward to multiple clinical catalysts over the next several quarters representing potential near-term value drivers, while we continue to advance our promising preclinical pipeline focused on the emerging areas of CAR-Tregs and transcriptional regulation, re

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.

Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast

Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to Decline

Beam Therapeutics

Cellectis SA

Calyxt

CRISPR Therapeutics

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century appeared first on InvestorPlace.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

bluebird bio

CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agriculture, chemical, pharmaceutical, and livestock industries.

CRISPR: 4 Emerging Players

Sangamo and licensee Pfizer's SB-525 is competing with BioMarin's ValRox in hemophilia A. There are durability questions surrounding both drugs.

Sangamo's Hemophilia A Treatment: An Assessment

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. “Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience an

Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4th at 11am Eastern Time. The virtual session will be webcast live and may be accessed on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website aft

Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call Transcript

News for Sangamo Therapeutics Stock (SGMO)